Back to News
Market Impact: 0.3
Belite Bio Announces NDA Submission In Japan For Tinlarebant Under Sakigake Designation
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Belite Bio submitted a New Drug Application in Japan for tinlarebant to treat Stargardt disease type 1. The drug has received Japan's SAKIGAKE designation, enabling an accelerated regulatory review process and potentially improving the timeline to commercialization in the market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
BLTE0.72
More News
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial
- Piero Cipollone: Interview with Milano Finanza